key: cord-0792654-4125rrzx authors: Ge, Y.; Sun, S.; Shen, Y. title: Estimation of case-fatality rate in COVID-19 patients with hypertension and diabetes mellitus in the New York State date: 2020-08-23 journal: nan DOI: 10.1101/2020.08.20.20178962 sha: 721471bfac1a3498c0ca318b0f99d5c5a5b615da doc_id: 792654 cord_uid: 4125rrzx We estimated the case-fatality rate (CFR) and ratios (RR) in adult COVID-19 cases with hypertension and diabetes mellitus in the New York State. We found that the elderly population had a higher CFR, but the elevated CFR ratios associated with comorbidities are more pronounced for the younger population. As of May 18, coronavirus disease 2019 (COVID-19) has affected more than 200 countries and 24 regions 1 . The New York state was heavily impacted by the coronavirus with more than 22 25 thousands of deaths 2 . Prior studies suggest that pre-existing health conditions such as 26 hypertension (HBP) and diabetes mellitus (DM) may exacerbate the severity of COVID-19 3 . 27 Quantitative assessments of the risk of death associated with them can inform the disease control 28 globally. However, few studies have estimated the corresponding case fatality rate for these two 29 comorbidities. 30 31 In this study, we aim to calculate the case-fatality rate (CFR) in adult COVID-19 cases with 32 hypertension and diabetes mellitus based on the publicly reported COVID-19 tracker data in the 33 New York State. 34 35 State-wide individual-level data of COVID-19 cases are not publicly available currently. In this 36 study, we aim to estimate CFR in COVID-19 patients with hypertension and diabetes mellitus 37 using aggregated level data from multiple sources. We first obtained the total number of 38 COVID-19 cases and deaths from public reports provided by the New York State Department of 39 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 23, 2020. The counts of confirmed cases were reported without age group information in New York State, 54 so we estimated the age group-specific number of cases according to the age distribution of 55 confirmed COVID-19 cases in the contiguous US reported from the Centers for Disease Control 56 and Prevention 5 . In addition, information on comorbidities at an aggregate level was only 57 reported for deaths but not all confirmed cases from the Tracker. To estimate the number of 58 cases with hypertension (C HBP ) or diabetes mellitus (C DM ), we multiplied the counts of confirmed 59 cases by the corresponding prevalence of hypertension and diabetes mellitus in the New York 60 State from BRFSS 4 2017, assuming that the susceptibility of COVID-19 infection for patients of 61 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. were two common comorbidities of COVID-19 cases with the estimated prevalence of 32.2% 72 (95% CI: 30.4%, 34.0%) and 11.9% (95% CI: 10.6%, 13.2%), respectively. As expected, the 73 prevalence of hypertension ( Figure 1A ) and diabetes mellitus ( Figure 1B) in COVID-19 cases 74 was highest among patients aged 65 years and above, with the case-fatality rate being 21.08% 75 (95% CI: 20.25%, 21.99%) for hypertension ( Figure 1C ) and 30.53% (95% CI: 28.11%, 33.40%) 76 for diabetes mellitus ( Figure 1D ). Compared with COVID-19 patients who were free of 77 hypertension, those with hypertension are associated with higher case-fatality rate ratios at 2.6 78 (95% CI: 2.3, 2.9), 1.7 (95% CI: 1.5, 1.8), and 1.0 (95% CI: 0.9, 1.1) for patients aged 18-44, 45-79 64, and 65+ y, respectively. The corresponding case-fatality rate ratios for diabetes mellitus were 80 15.2 (95% CI: 12.2, 19.9), 4.1 (95% CI: 3.6, 4.6), and 1.7 (95%CI: 1.5, 1.9), respectively ( Figure 81 1E). 82 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178962 doi: medRxiv preprint 5 83 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178962 doi: medRxiv preprint information from data sources of CDC and BRFSS to estimate age distribution and comorbidity 100 prevalence. Those estimations may be biased. In addition, with no individual-level data available 101 for the analyses, further investigations such as the interactions between comorbidities were not 102 conducted. 103 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178962 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178962 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. World Health Organization. Coronavirus disease (COVID-19) pandemic New York State Department of Health. Novel Coronavirus (COVID-19) Covid-19: risk factors for severe disease and death CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 23, 2020. . https://doi.org/10.1101/2020.08.20.20178962 doi: medRxiv preprint